Dianthus Therapeutics, Inc. (DNTH) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
5.86
↑+303% vs avg
5yr avg: 1.45
30Y Low0.3·High4.0
ROE
↓
-38.4%
↑-39% vs avg
5yr avg: -27.7%
30Y Low-120%·High-8%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DNTH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Dianthus Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.2B | $1.6B | $726M | $54M | $24M | $243M | $344M | $561M | $190M | — | — |
| Enterprise Value | $3.1B | $1.5B | $705M | $-78144401 | $9M | $112M | $286M | $496M | $132M | — | — |
| P/E Ratio → | -18.20 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1567.68 | 764.98 | 116.48 | 18.97 | 3.69 | 164.92 | — | — | — | — | — |
| P/B Ratio | 5.86 | 3.16 | 2.06 | 0.32 | 0.32 | 1.41 | 2.39 | 3.97 | 1.30 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DNTH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 740.57 | 113.06 | -27.65 | 1.42 | 75.73 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
DNTH Profitability
Margins and return-on-capital ratios measuring operating efficiency
Dianthus Therapeutics, Inc. earns an operating margin of -8739.3%. Operating margins have compressed from -1704.7% to -8739.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -38.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | -8739.3% | -8739.3% | -1633.7% | -1704.7% | -462.9% | -886.6% | — | — | — | — | — |
| Net Profit Margin | -7973.3% | -7973.3% | -1362.8% | -1541.2% | -443.8% | -888.1% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -38.4% | -38.4% | -32.6% | -35.9% | -23.1% | -8.3% | -52.6% | -53.5% | -58.7% | -119.6% | -104.3% |
| ROA | -35.9% | -35.9% | -30.7% | -33.2% | -20.9% | -7.5% | -46.4% | -48.2% | -54.3% | -107.9% | -83.2% |
| ROIC | -34.4% | -34.4% | -41.5% | -75.1% | -44.5% | -15.5% | -72.9% | -76.2% | -104.5% | -1647.4% | — |
| ROCE | -41.6% | -41.6% | -38.8% | -39.4% | -23.4% | -7.9% | -52.9% | -56.4% | -60.8% | -120.4% | -102.5% |
DNTH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $51M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -0.06 | -0.78 | -0.20 | -0.76 | -0.40 | -0.46 | -0.40 | -1.02 | -0.50 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -19.90 | — | — | — | -56.86 |
Net cash position: cash ($51M) exceeds total debt ($1M)
DNTH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Dianthus Therapeutics, Inc.'s current ratio of 13.32x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 18.42x to 13.32x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.32 | 13.32 | 15.22 | 18.42 | 9.97 | 16.63 | 13.26 | 10.62 | 13.95 | 12.68 | 4.71 |
| Quick Ratio | 13.32 | 13.32 | 15.22 | 18.42 | 9.97 | 16.63 | 13.26 | 10.62 | 13.95 | 12.68 | 4.71 |
| Cash Ratio | 13.16 | 13.16 | 14.92 | 18.04 | 9.18 | 16.29 | 13.02 | 10.32 | 13.68 | 12.45 | 1.98 |
| Asset Turnover | — | 0.00 | 0.02 | 0.02 | 0.08 | 0.01 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 18.29 | 47.24 | 61.74 | 320.69 | — | — | — | — | — | — |
DNTH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Dianthus Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $38M | $33M | $5M | $4M | $3M | $3M | $2M | $2M | $2M | $2M |
Peer Comparison
Compare DNTH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DNTHYou | $3B | -18.2 | — | — | 100.0% | -8739.3% | -38.4% | -34.4% | — |
 ALXO | $82M | -0.8 | — | — | — | — | -145.7% | -122.0% | — |
 BCAB | $4M | -0.1 | — | — | 100.0% | -2965.3% | — | — | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 RCUS | $2B | -7.1 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 APLS | $5B | 227.9 | 92.5 | 116.7 | 89.8% | 5.5% | 7.5% | 12.3% | 8.5 |
 OMAB | $5B | 15.5 | 9.5 | 11.2 | 75.6% | 56.0% | 48.6% | 31.7% | 1.4 |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 VKTX | $3B | -9.0 | — | — | — | — | -47.3% | -44.4% | — |
 INVA | $2B | 6.8 | 6.7 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 CABA | $491M | -1.8 | — | — | — | — | -127.0% | -429.6% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
What if you invested $1,000 in DNTH 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in DNTH be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs DNTH Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationDNTH vs ALXO — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs ALX Oncology Holdings Inc..
Compare NowDNTH — Frequently Asked Questions
Quick answers to the most common questions about buying DNTH stock.
What is Dianthus Therapeutics, Inc.'s P/E ratio?
Dianthus Therapeutics, Inc.'s current P/E ratio is -18.2x. This places it at the 50th percentile of its historical range.
What is Dianthus Therapeutics, Inc.'s ROE?
Dianthus Therapeutics, Inc.'s return on equity (ROE) is -38.4%. The historical average is -52.7%.
Is DNTH stock overvalued?
Based on historical data, Dianthus Therapeutics, Inc. is trading at a P/E of -18.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Dianthus Therapeutics, Inc.'s profit margins?
Dianthus Therapeutics, Inc. has 100.0% gross margin and -8739.3% operating margin.